Navigation Links
P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth
Date:10/29/2008

,026 $20,199 9%

COST OF PRODUCTS SOLD 10,905 9,519 15%

GROSS MARGIN 11,121 10,680 4%

SELLING, GENERAL & ADMINISTRATIVE

EXPENSE 6,436 6,262 3%

OPERATING INCOME 4,685 4,418 6%

TOTAL INTEREST EXPENSE 339 359

OTHER NON-OPERATING INCOME, NET 337 193

EARNINGS BEFORE INCOME TAXES 4,683 4,252 10%

INCOME TAXES 1,335 1,173

NET EARNINGS 3,348 3,079 9%

EFFECTIVE TAX RATE 28.5% 27.6%

PER COMMON SHARE:

BASIC NET EARNINGS $1.10 $0.97 13%

DILUTED NET EARNINGS $1.03 $0.92 12%

DIVIDENDS $0.40 $0.35 14%

AVERAGE DILUTED SHARES OUTSTANDING 3,239.5 3,354.2

Basis Pt

COMPARISONS AS A % OF NET SALES Chg

COST OF PRODUCTS SOLD 49.5% 47.1% 240

GROSS MARGIN 50.5% 52.9% (240)

SELLING, GENERAL & ADMINISTRATIVE

EXPENSE 29.2% 31.0% (180)

OPERATING MARGIN 21.3% 21.9% (60)

EARNINGS BEFORE INCOME TAXES 21.3% 21.1% 20

NET EARNINGS 15.2% 15.2% -

THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES

(Amounts in Millions)

Consolidated Earnin
'/>"/>

SOURCE The Procter & Gamble Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Cardinal Health Reports First Quarter Results
2. uKarma Reports Progress With International Distribution Agreement for Its Xflowsion DVD Series
3. STAAR Surgical Reports 33% Third Quarter Revenue Growth
4. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
5. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
6. LCA-Vision Reports Third Quarter 2008 Financial Results
7. Universal Health Services, Inc. Reports 2008 Third Quarter Results
8. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
9. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
10. WellPoint Reports Third Quarter 2008 Results
11. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)..., Results of St. Jude study could shape new treat...., Jan. 8 Scientists at...trated a more effective treatment for bacterial pn...ntibiotics clindamycin and azithromycin, which kil...are more effective than a standard first-line trea...
(Date:1/8/2009)...eview says it lowered bad cholesterol more effecti...althDay News) -- After nearly a year of review, U....ted the continued use of the controversial cholest... Drug Administration said there was no significant...tients taking Vytorin and patients taking the drug...
(Date:1/8/2009)..., BETHESDA, Md., Jan. 8 /PRNewswire-FirstCall/ -...pleased to announce that throughout the fourth qua..., Orthotics Center, Rocky Mountain Orthotic-Prosth...Services, Inc., First Coast Orthotics & Prosth.... These acquisitions add patient care centers to e...
(Date:1/8/2009)..., SAN FRANCISCO, Jan. 8 /PRNewswire-FirstCall...ounced that David Hung, M.D., president and chief,...l J.P. Morgan Healthcare,Conference on Wednesday,...tin,St. Francis Hotel in San Francisco. , ...d its clinical,development programs for Dimebon f...
Breaking Medicine News(10 mins):Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2
...management program cuts diabetes risk and is more ...s index (BMI) in overweight children. A family-b...chers at Yale School of Medicine was more successf...MI and insulin sensitivity than traditional clinic...
...rier cities like the Indian capital but also modif... warns a UN report released Wednesday. "Much of ...al areas from which they were first displaced," sa...lation 2007' report of the United Nations Populati...
...in Pakistan, evoking mixed reactions. <brThe...something extraordinary. Then the Lahore High Cou...comes as a pleasant surprise is the decision of th...e Court to release them on bail and hear their ap...
...ua, today welcomed Labors preventative health care... addressing Australias future health needs. Dr Ca...s ageing population and the increasing incidence o...including among younger people, will place great s...
Other Medicine News:Health News:Bright Bodies Weight Program Lowers Diabetes Risk, BMI in Obese Kids 2Health News:Same Sex Pair Get Relief in Pakistan 2Health News:Labor's Preventive Health Care Policy Looks to Address Future Needs 2
(Date:1/9/2009)...wire-FirstCall/ -- ProUroCare Medical Inc. (OTC Bu...of 3,050,000 units at $1.00 per unit, each unit co...emable warrant to purchase one share of common sto...mpany has granted the underwriter of the offering ...7,500 units to cover over-allotments, if any. The ...
(Date:1/9/2009)...re/ -- ESBATech AG, a leading developer of antibod...ation of the Phase I/IIa clinical development of i...eoarthritis (OA). This double-blind, randomized, p...signed to investigate the safety, tolerability and... intra-articular administration to patients with s...
(Date:1/8/2009)...wswire-FirstCall/ -- , - ThromboGenics, Lea...omacular Adhesion in the US and Europe , Th...nology company,focused on innovative treatments f...unces today that it has started the Phase III clin... treatment of back of the eye disease, the,final ...
(Date:1/8/2009)... second indication with clinical-stage, systemical...EMONT, Calif., Jan. 8 Quark Pharma...l company discovering and developing novel RNA int...ed that it has initiated patient dosing in its Pha... administered siRNA drug candidate QPI-1002 (previ...
Breaking Medicine Technology:ProUroCare Medical Inc. Announces Pricing of Equity Offering 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 4ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 2ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 3ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 4Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 2Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 3Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function 4Tips from the Journals of the American Society for Microbiology 107 1Tips from the Journals of the American Society for Microbiology 107 2Tips from the Journals of the American Society for Microbiology 107 3Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 109 1Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer 109 2St Jude influenza survey uncovers key differences between bird flu and human flu 106 1St Jude influenza survey uncovers key differences between bird flu and human flu 106 2St Jude influenza survey uncovers key differences between bird flu and human flu 106 3Stanford study highlights cost effective method of lowering heart disease risks 104 1Stanford study highlights cost effective method of lowering heart disease risks 104 2Stanford study highlights cost effective method of lowering heart disease risks 104 3
...ent with ISIS 301012 produced at least 45% additio...ded to,maximally-tolerated lipid-lowering therapie...tCall/ -- Isis,Pharmaceuticals, Inc. announced upd...al of ISIS 301012 in patients with homozygous,fami...of which were,presented in March at the of Cardiol...
...from Phase III pivotal trial demonstrate safety an...rol fumarate for,patients with moderate to severe ...- Dey, L.P. announced,that two clinical data prese...ence of the American Thoracic Society (ATS) on,Sun...o. The,presentations will detail Phase III clinica...
Other Medicine Technology:Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 2Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 3Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 4Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 5Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007 2Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007 3Clinical Trial Data for Perforomist Inhalation Solution to be,Presented at ATS on May 20, 2007 4
The PK Plasma-CISE™ (wire electrodes) and Plasma-CUT™ (coiled electrodes) are single use devices that produce precise, consistent tissue cutting with minimal thermal spread and Vapor seal
...gle use device that produces rapid, consistent, pr...nd vapor sealing of adjacent tissue for prostatic ...ccation. Often referred to as PlasmaKinetic vapori...the urologist the control needed to achieve the an...
Medium Surgical Clips. 6 clips per cartridge. Box of 30 cartridges with a total of 180 titanium clips per box. For secure vasal and other occlusion.
Sterile Disposable Thermal Cautery Tips for Vasectomy. Individually peel-pouched with dual plastic sheaths to cover non-sterile handle. Box of 10 tips.
Medicine Products: